Literature DB >> 23338282

Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS.

Axel Methner1, Frauke Zipp.   

Abstract

2012 witnessed important developments for multiple sclerosis, including successful phase III trials of novel oral therapeutics and identification of the potassium channel KIR4.1 as an autoimmune target. Additionally, the lung was highlighted as an important site for immune-cell programming, and the relevance of a TNF receptor variant was clarified.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23338282     DOI： 10.1038/nrneurol.2012.277

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


  10 in total

1.  Placebo-controlled trial of oral laquinimod for multiple sclerosis.

Authors:  Giancarlo Comi; Douglas Jeffery; Ludwig Kappos; Xavier Montalban; Alexey Boyko; Maria A Rocca; Massimo Filippi
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

2.  Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

Authors:  Ralf A Linker; De-Hyung Lee; Sarah Ryan; Anne M van Dam; Rebecca Conrad; Pradeep Bista; Weike Zeng; Xiaoping Hronowsky; Alex Buko; Sowmya Chollate; Gisa Ellrichmann; Wolfgang Brück; Kate Dawson; Susan Goelz; Stefan Wiese; Robert H Scannevin; Matvey Lukashev; Ralf Gold
Journal:  Brain       Date:  2011-03       Impact factor: 13.501

3.  Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Authors:  Robert J Fox; David H Miller; J Theodore Phillips; Michael Hutchinson; Eva Havrdova; Mariko Kita; Minhua Yang; Kartik Raghupathi; Mark Novas; Marianne T Sweetser; Vissia Viglietta; Katherine T Dawson
Journal:  N Engl J Med       Date:  2012-09-20       Impact factor: 91.245

4.  Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Authors:  Ralf Gold; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Gavin Giovannoni; Krzysztof Selmaj; Carlo Tornatore; Marianne T Sweetser; Minhua Yang; Sarah I Sheikh; Katherine T Dawson
Journal:  N Engl J Med       Date:  2012-09-20       Impact factor: 91.245

5.  Insight into the mechanism of laquinimod action.

Authors:  W Brück; C Wegner
Journal:  J Neurol Sci       Date:  2011-03-22       Impact factor: 3.181

6.  Potassium channel KIR4.1 as an immune target in multiple sclerosis.

Authors:  Rajneesh Srivastava; Muhammad Aslam; Sudhakar Reddy Kalluri; Lucas Schirmer; Dorothea Buck; Björn Tackenberg; Veit Rothhammer; Andrew Chan; Ralf Gold; Achim Berthele; Jeffrey L Bennett; Thomas Korn; Bernhard Hemmer
Journal:  N Engl J Med       Date:  2012-07-12       Impact factor: 91.245

7.  T cells become licensed in the lung to enter the central nervous system.

Authors:  Francesca Odoardi; Christopher Sie; Kristina Streyl; Vijay K Ulaganathan; Christian Schläger; Dmitri Lodygin; Klaus Heckelsmiller; Wilfried Nietfeld; Joachim Ellwart; Wolfgang E F Klinkert; Claudio Lottaz; Mikhail Nosov; Volker Brinkmann; Rainer Spang; Hans Lehrach; Martin Vingron; Hartmut Wekerle; Cassandra Flügel-Koch; Alexander Flügel
Journal:  Nature       Date:  2012-08-30       Impact factor: 49.962

8.  Effects of dimethyl fumarate on neuroprotection and immunomodulation.

Authors:  Philipp Albrecht; Imane Bouchachia; Norbert Goebels; Nadine Henke; Harald H Hofstetter; Andrea Issberner; Zsuzsa Kovacs; Jan Lewerenz; Dmitrij Lisak; Pamela Maher; Anne-Kathrin Mausberg; Kim Quasthoff; Corinna Zimmermann; Hans-Peter Hartung; Axel Methner
Journal:  J Neuroinflammation       Date:  2012-07-07       Impact factor: 8.322

9.  Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity.

Authors:  Ulf Schulze-Topphoff; Aparna Shetty; Michel Varrin-Doyer; Nicolas Molnarfi; Sharon A Sagan; Raymond A Sobel; Patricia A Nelson; Scott S Zamvil
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

10.  TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis.

Authors:  Adam P Gregory; Calliope A Dendrou; Kathrine E Attfield; Aiden Haghikia; Dionysia K Xifara; Falk Butter; Gereon Poschmann; Gurman Kaur; Lydia Lambert; Oliver A Leach; Simone Prömel; Divya Punwani; James H Felce; Simon J Davis; Ralf Gold; Finn C Nielsen; Richard M Siegel; Matthias Mann; John I Bell; Gil McVean; Lars Fugger
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962
  10 in total
  7 in total

1.  Thiamine deficiency promotes T cell infiltration in experimental autoimmune encephalomyelitis: the involvement of CCL2.

Authors:  Zhe Ji; Zhiqin Fan; Ying Zhang; Ronghuan Yu; Haihua Yang; Chenghua Zhou; Jia Luo; Zun-Ji Ke
Journal:  J Immunol       Date:  2014-07-25       Impact factor: 5.422

2.  Disulfiram and Diphenhydramine Hydrochloride Upregulate miR-30a to Suppress IL-17-Associated Autoimmune Inflammation.

Authors:  Ming Zhao; Dingya Sun; Yangtai Guan; Zhihong Wang; Daoqian Sang; Mingdong Liu; Yingyan Pu; Xue Fang; Dan Wang; Aijun Huang; Xiaoying Bi; Li Cao; Cheng He
Journal:  J Neurosci       Date:  2016-08-31       Impact factor: 6.167

3.  Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB.

Authors:  Jan P Nicolay; Karin Müller-Decker; Anne Schroeder; Markus Brechmann; Markus Möbs; Cyrill Géraud; Chalid Assaf; Sergij Goerdt; Peter H Krammer; Karsten Gülow
Journal:  Blood       Date:  2016-06-06       Impact factor: 22.113

4.  LncRNA GAS5 inhibits microglial M2 polarization and exacerbates demyelination.

Authors:  Dingya Sun; Zhongwang Yu; Xue Fang; Mingdong Liu; Yingyan Pu; Qi Shao; Dan Wang; Xiaolin Zhao; Aijun Huang; Zhenghua Xiang; Chao Zhao; Robin Jm Franklin; Li Cao; Cheng He
Journal:  EMBO Rep       Date:  2017-08-14       Impact factor: 8.807

5.  Clozapine reduces infiltration into the CNS by targeting migration in experimental autoimmune encephalomyelitis.

Authors:  Katharina Robichon; Vimal Patel; Bronwen Connor; Anne Camille La Flamme
Journal:  J Neuroinflammation       Date:  2020-02-12       Impact factor: 8.322

6.  1,25-Dihydroxyvitamin D3 Protects against Immune-Mediated Killing of Neurons in Culture and in Experimental Autoimmune Encephalomyelitis.

Authors:  Scott Sloka; Simon Zhornitsky; Claudia Silva; Luanne M Metz; V Wee Yong
Journal:  PLoS One       Date:  2015-12-17       Impact factor: 3.240

7.  Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity.

Authors:  Yingying Huang; Qiqi Mao; Jian He; Jing Su; Yi Peng; Wei Liang; Zixi Hu; Sufang Zhou; Xiaoling Lu; Yongxiang Zhao
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.